Interferon Lambda-3 (IFNL3) Antibody
260€ (50 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Interferon Lambda-3 (IFNL3) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx339614
tested applications
ELISA, WB
Description
IFNL3 Antibody is a Rabbit Polyclonal against IFNL3.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Interferon Lambda-3 (IFNL3) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | ELISA: 1/1000 - 1/2000, WB: 1/200 - 1/1000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Antigen Affinity Chromatography. |
| Size 1 | 50 µl |
| Size 2 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, WB |
| Buffer | PBS, pH 7.4, containing 0.05% NaN3 and 40% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q8IZI9 |
| Gene ID | 282617 |
| Alias | IL28B,IL28C,IL-28B,IL-28C,IFN-lambda-3,IFN-lambda-4,Cytokine Zcyto22,Interleukin-28B,Interleukin-28C |
| Background | Antibody anti-IFNL3 |
| Status | RUO |
Descripción
Interferon Lambda 3 (IFNL3), also known as IL-28B, is a cytokine that belongs to the Type III interferon family, which plays a critical role in the innate immune system, particularly in antiviral defense. IFNL3, like other Type III interferons, activates signaling pathways that result in the expression of interferon-stimulated genes (ISGs), creating an antiviral state within cells. IFNL3 primarily targets epithelial cells, such as those lining the respiratory tract, gastrointestinal tract, and liver, which are common entry points for viral infections. The discovery of IFNL3 and its genetic variations has been of significant interest, especially due to its role in the treatment and clearance of hepatitis C virus (HCV) infections. Genetic polymorphisms in the IFNL3 gene are strong predictors of treatment response in HCV patients, influencing outcomes of both spontaneous viral clearance and antiviral therapy. This connection has made IFNL3 a focus of research in viral infections, where immune response to chronic infections is crucial.
Related Products
Bovine IFNL3 (Interferon lambda 3) ELISA Kit
Ver Producto
Human IL28B (Interleukin-28B) ELISA Kit
Ver Producto